Good morning :)
$
₹
Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY

NYSE
Asset Logo

Bristol-Myers Squibb Company

BMY

NYSE
$64.140.79% (+0.50)
$
₹
$64.140.79% (+0.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - General

Large Cap

With a market cap of $130.0B the stock is ranked 132

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

14.01
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.82
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$4.54
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

17.71
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

18.87%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

3.94%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 29 analysts' reports

Buy
10 analysts
Hold
18 analysts
Sell
1 analyst

Analysts expect a +3.29% price upside over the next year

Current Price$64.14
Target Price$66.20

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
37.45
37.45
1Y Return
52.36%
52.36%
Buy Reco %
77.41
77.41
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
30.77
30.77
1Y Return
51.07%
51.07%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.14
115.14
1Y Return
78.78%
78.78%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
20.71
20.71
1Y Return
12.71%
12.71%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
23.97
23.97
1Y Return
5.95%
5.95%
Buy Reco %
90.00
90.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Bristol-Myers Squibb Company 14.015.8217.71
Eli Lilly and Company37.4529.351.10
Johnson & Johnson30.777.532.78

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

12.2
2.2
12.5
1
11.4
2.6
12.9
3.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue11.8612.2011.8912.3411.2012.2612.2212.5011.4812.97
Net Income-11.911.681.210.072.451.312.201.082.673.31
Net Profit Margin-100.38%13.76%10.18%0.58%21.92%10.67%18.00%8.69%23.30%25.56%
See CostsAll values in $ Billion

Frequently asked questions

Frequently asked questions

  1. Bristol-Myers Squibb Company (BMY) share price today is $64.14 as of September 15, 2026 at 1:30 AM IST. The stock touched a day high of $65.05 and a day low of $63.92.

  2. Bristol-Myers Squibb Company stock trades on NYSE under the ticker symbol BMY.

  3. Bristol-Myers Squibb Company's market capitalization is $129.99B as of September 15, 2026 at 1:30 AM IST.

  4. Bristol-Myers Squibb Company's price-to-earnings (P/E) ratio is 14.01 as of September 14, 2026.

  5. Bristol-Myers Squibb Company's price-to-book (P/B) ratio is 5.82 as of September 14, 2026.

  6. Yes, Bristol-Myers Squibb Company pays a dividend, with a current dividend yield of 3.94%.

  7. Yes, You can buy Bristol-Myers Squibb Company shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Bristol-Myers Squibb Company shares in three steps: 1. Search Bristol-Myers Squibb Company on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Bristol-Myers Squibb Company trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Bristol-Myers Squibb Company (BMY) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1558 shares at the current price of $64.14.

Loading...